Skip to main content

Table 1 Participants characteristics

From: Stage-dependent association of BDNF and TGF-β1with lung function in stable COPD

 

COPD

Control

p

 

all

GOLD 2

GOLD 3

GOLD 4

 

COPD (all) vs. Control

 

n = 63

n = 22

n = 28

n = 13

n = 17

Age

64.0

67.0

63.0

62.0

62.0

0.96

(years)

[43…79]

[45…78]

[43…76]

[51…79]

[51…73]

 

Body Mass Index

24.8

29.4

23.4

23.8

27.4

0.40

(kg*m-2)

[13.6…46.5]

[19.3…39.7]

[13.6…46.5]

[15.8…32.0]

[22.9…57.1]

pack years

40.0

41.5

42.0

34.0

25.0

< 0.001

 

[0…100]

[0…100]

[18…75]

[20…60]

[20…40]

 

Smoking history

     

-

never/active/former

2 / 11 / 48

1 / 6 / 14

1 / 5 / 21

0 / 0 / 13

0 / 1 / 16

 

Inhaled medication

     

-

LABA/LAMA/ICS

59 / 58 / 49

21 / 19 / 20

25 / 26 / 18

13 / 13 / 11

0 / 0 / 0

 

Oral medication

     

-

OCS/PDE-I/TPH

13 / 5 / 10

3 / 0 / 2

7 / 2 / 5

3 / 3 / 3

0 / 0 / 0

 

Hemoglobin

14.4

14.3

14.7

13.8

11.6

< 0.001

(mg/l)

[10.3…16.9]

[10.3…16.4]

[10.4…16.9]

[11.6…16.8]

[9.6…14.8]

 

Hematocrit

42.4

42.4

42.8

42.0

35.7

< 0.001

(%)

[31.1…49.9]

[31.1…47.4]

[31.1…49.9]

[37.6…49.4]

[27.8…41.6]

 

Platelets

292

239

322

293

289

0.56

(*109/l)

[145…787]

[172…417]

[154…787]

[145…504]

[177…569]

 

Leukocytes

8.6

8.1

9.4

8.7

8.7

0.69

(*109/l)

[6.1…18.3]

[6.2…11.9]

[6.1…18.3]

[6.8…17.8]

[6.4…11.6]

 

FEV 1 total

1.13

1.46

1.11

0.69

2.32

< 0.001

(l)

[0.45…2.34]

[0.96…2.34]

[0.76…1.76]

[0.45…0.91]

[1.33…4.24]

 

FEV 1 % pred.

42.6

58.2

41.1

27.4

76.1

< 0.001

(%)

[16.3…76.2]

[50.3…76.2]

[30.0…48.5]

[16.3…29.7]

[55.2…145.8]

 

FEV 1 % VC

46.9

57.8

45.3

34.5

83.3

< 0.001

(%)

[22.2…67.0]

[41.7…67.0]

[30.2…63.8]

[22.2…49.3]

[71.0…99.7]

 

MEF25 total

0.25

0.31

0.25

0.17

1.02

< 0.001

(l/s)

[0.10…0.62]

[0.13…0.62]

[0.12…0.38]

[0.10…0.36]

[0.36…4.58]

 

MEF25 % pred.

18.8

24.7

17.5

12.9

62.3

< 0.001

(%)

[7.3…41.4]

[10.9…41.4]

[8.8…32.1]

[7.3…30.0]

[29.6…286.0]

 

RV total

4.46

3.62

4.76

6.05

2.60

< 0.001

(l)

[2.27…8.48]

[2.72…5.37]

[2.27…8.48]

[3.66…8.26]

[1.12…3.76]

 

RV % pred.

200.6

158.5

203.6

273.7

113.9

< 0.001

(%)

[101.9…376.8]

[114.0…240.1]

[101.9…376.8]

[204.5…317.5]

[48.1…146.8]

 

TLC total

7.09

6.17

7.21

8.46

5.40

< 0.01

(l)

[4.1…14.09]

[5.1…8.9]

[4.1…11.7]

[5.0.…14.1]

[3.0…8.2]

 

TLC % pred.

116.8

111.1

116.8

135.8

84.5

< 0.001

(%)

[71.5…179.2]

[83.3…149.1]

[71.5…169.5]

[107.5…179.2]

[52.3…111.0]

 

RV % TLC

64.8

57.4

65.2

73.5

50.1

< 0.001

(%)

[45.1…86.2]

[45.1…70.6]

[52.3…73.6]

[65.4…86.2]

[26.5…63.5]

 

TLCO / VA total

0.69

0.84

0.64

0.37

1.03

< 0.001

(mmol/min/kPa/l)

[0.01…1.72]

[0.37…1.72]

[0.13…1.27]

[0.01…0.90]

[0.72…1.91]

 

TLCO / VA % pred.

49.0

60.3

42.3

27.8

77.6

< 0.001

(%)

[0.95…105.4]

[25.6…105.4]

[8.0…89.1]

[0.95…68.6]

[57.3…138.5]

 
  1. Data are shown as median [minimum…maximum]. LABA – long-acting beta agonist, LAMA – long acting muscarinic antagonist, ICD – inhaled corticosteroids, OCS – oral corticosteroids, PDE-I – phosphodiesterase inbibitor, TPH – theophylline.
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us